Pfizer PainKiller Bextra withdrawn from market, New Boxed Warnings for Celebrex Thu, 07 Apr 2005 Pfizer’s withdrawal of the COX-2 pain reliever, Bextra, from the market because of potentially lethal side effects, including increased risk of cardiovascular malfunction and severe rash, validates Dr. David Graham’s analysis. This FDA medical expert…
FDA Approves Lilly’s Growth Hormone for Healthy Children Mon, 28 Jul 2003 The FDA has approved Eli Lilly’s injectable human growth hormone (hGH) therapy, Humatrope, for healthy children who are short but have no hormonal deficiency. Lilly claims that its trials in 300 healthy short children resulted in an increase…
Pfizer Statements RE: Bextra, Celebrex, Neurontin Shown to be Lies Fri, 08 Apr 2005 The New York Times reports that “as recently as Tuesday [Pfizer] assured Wall Street that sales of Celebrex and Bextra would soon rebound. It was the latest in a string of announcements by the company regarding…
Asthma Drug trial Halted -Health Risk Are Suspected Mon, 17 Mar 2003 A spate of recent articles have shown that pharmaceutical companies suppress the publication of negative findings about their products. However, that is not the only way these companies keep physicians and patients uninformed about adverse drug effects. Another…
Drug Warnings: Are They Effective? USA Today Tue, 26 Apr 2005 How effective are drug warnings? USA Today reports that experts are unsure. For example, a study in the January issue of Pharmacoepidemiology and Drug Safety focused on Ohio Medicaid claims for Rezulin prescriptions – the diabetes drug had been…
Cost and Consequence: drug “cocktails” deplete Medicaid_Globe Tue, 24 Jun 2003 The escalating cost of healthcare is in large measure due tothe spiraling expenditure on drugs–many of which are misprescribed.The Boston Globe reports about one Medicaid patient who is prescribed18 medications at a cost of roughly $16,000 a year–“all at…
FDA Scientist Won’t Present New Pain Drug Data – FDA to Create Independent Drug Safety Board Tue, 15 Feb 2005 A culture of intimidation prevents FDA safety officers from disclosing important safety information about widely marketed drugs. Reuters reports: “Criticism of how the FDA monitors the after-market safety of drugs…
“The Drug Trial That Went Wrong” is an investigative report by Chanel 4 (UK) about the circumstances surrounding the near fatal drug trial testing the safety of TGN1412, a monoclonal antibody drug, conducted in March 2006 at London’s Northwick Park Hospital. [1] http://news.bbc.co.uk/go/pr/fr/-/1/hi/health/5377226.stm It airs momorrow.
The New York Times reports that a Maryland psychiatrist, Dr. Peter Gleason, was handcuffed and arrested in March and charged with criminal promotion of a drug "for purposes other than those approved by the federal government."
“There is a crisis of credibility in medicine and science,” says Dr Joseph Sonnabend who, as a former virologist for the Medical Research Council and a retired Aids physician, has watched the basis for public confidence decline.
A front page report in The New York Times provides additonal information about the catastrophic TGN1412 medical experiment in which 6 previously healthy volunteers were intravenously injected with monoclonal antibody in a highly risky procedure.
The independent Institute of Science in Society (ISIS) challenges the report issued by the UK government medicines oversight agency, MHRA (equivalent to US FDA), absolving itself and those involved from any responsibility for a catastrophic human experiment that nearly killed six healthy volunteers.
